6 terminated, 2 completed, 1 withdrawn. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 6, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow ARC-520: new trials by email Literature Review of ARC-520 trials Research Report on ARC-520
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection ARC-520 Injection, entecavir, tenofovir - Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 12 | 2016-03-01 | 2026-01-13 |
| Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) ARC-520, entecavir, pegylated interferon alpha 2a - Hepatitis B, Hepatitis D | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 79 | 2015-12-01 | 2026-01-13 |
| A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection ARC-520, Placebo, entecavir - Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 32 | 2015-11-01 | 2026-01-13 |
| A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection ARC-520 Injection, placebo, entecavir - Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 58 | 2015-09-01 | 2026-01-13 |
| A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers ARC-520, cetirizine, diphenhydramine - Healthy | Phase 1 | Completed | Arrowhead Pharmaceuticals | 40 | 2015-09-01 | 2026-01-13 |
| Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus ARC-520, Placebo, Entecavir - Chronic Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 4 | 2015-08-01 | 2025-11-03 |
| Study of ARC-520 in Patient With Chronic Hepatitis B Virus ARC-520 Injection - Chronic Hepatitis B | Phase 2 | Withdrawn | Arrowhead Pharmaceuticals | 2015-02-01 | 2025-12-26 | |
| A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection ARC-520, Placebo, entecavir - Hepatitis B, Chronic | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 58 | 2014-03-01 | 2026-01-13 |
| Safety and Tolerability Study of ARC-520 in Healthy Volunteers ARC-520, Placebo - Healthy | Phase 1 | Completed | Arrowhead Pharmaceuticals | 54 | 2013-07-01 | 2025-12-26 |
Hepatitis B (6) · Hepatitis B, Chronic (3) · Hepatitis (1) · Hepatitis D (1)
Australia (4) · China (4) · South Korea (4) · Germany (3) · Bulgaria (1) · Hong Kong (1) · Moldova (1) · New Zealand (1) · Taiwan (1) · Thailand (1) · United States (1)
Bruce Given, MD (1) · Jason Lickliter, MD, PhD (1)
2014 (3), 2015 (1)